Athena Diagnostics filed its petition for certiorari with the U.S. Supreme Court yesterday in Athena Diagnostics v. Mayo Collaborative Services. There is a strong argument for the Court to grant the petition, and patent stakeholders on all sides are sure to weigh in via amicus briefs over the next month. The petition could represent the best chance for clarifying Section 101 law in the near-term, since patent reform efforts on the topic have been seemingly stalled. Below are a few initial reactions from the patent community to Athena’s arguments.
Business
- USPTO Ramps Up Efforts to Promote Women Entrepreneurs
- Sign the Prenup: What Brands Can Learn From the Kanye West/Adidas IP Breakup
- Lessons from the Levandowski Case: Reimagining the Exit Interview as Risk Management
- Advocating for Ethics-Driven Regulation for Blockchain Technologies
- Panelists Highlight Increased Capital, Importance of Foreign Patents for U.S. Patent Monetization at IPWatchdog LIVE 2022
Recent Posts
- Other Barks & Bites for Friday, November 25: Seventh Circuit Nixes Publicity Claim Against Subscriber List Sale, Copyright Office and USPTO Announce NFT Study, and Alia Moses Takes Over as Chief Judge of Western Texas
- What IP Stakeholders are Giving Thanks for in 2022
- NYIPLA Tells Supremes IP Lawyers Need Attorney-Client Privilege for Dual-Purpose Communications
- The Fraction-of-a-Fraction Problem—Why the Math Doesn’t Support Blaming Drug Patents for the High Cost of U.S. Healthcare
- A Guide to Disclosures in Delaware Patent Litigation in the Face of Pending Federal Circuit Review